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Abstract
Introduction A loss of p53 function resulting from mutation is
prevalent in human cancers. Thus, restoration of p53 function to
mutant p53 using small compounds has been extensively
studied for cancer therapy. We previously reported that PRIMA-
1 (for 'p53 reactivation and induction of massive apoptosis')
restored the transcriptional activity of p53 target genes in breast
cancer cells with a p53 mutation. By using functional
proteomics approach, we sought to identify molecular targets
that are involved in the restoration of normal function to mutant
p53.
Methods PRIMA-1 treated cell lysates were subjected to
immunoprecipitation with DO-1 primary antibody against p53
protein, and proteins bound to p53 were separated on a
denaturing gel. Bands expressed differentially between control
and PRIMA-1-treated cells were then identified by matrix-
assisted laser desorption ionization-time-of-flight spectrometry.
Protein expression in whole cell lysates and nuclear extracts
were confirmed by Western blotting. The effect of combined
treatment of PRIMA-1 and adriamycin in breast cancer cells was
determined with a cytotoxicity assay in vitro.
Results PRIMA-1 treated cells distinctly expressed a protein
band of 90 kDa that was identified as heat shock protein 90
(Hsp90) by the analysis of the 90 kDa band tryptic digest.
Immunoblotting with isoform-specific antibodies against Hsp90
identified this band as the α  isoform of Hsp90 (Hsp90α ). Co-
immunoprecipitation with anti-Hsp90α  antibody followed by
immunoblotting with DO-1 confirmed that p53 and Hsp90α
were interacting proteins. PRIMA-1 treatment also resulted in
the translocation of Hsp90α  to the nucleus by 8 hours.
Treatment of cells with PRIMA-1 alone or in combination with
adriamycin, a DNA-targeted agent, resulted in increased
sensitivity of tumor cells.
Conclusion The studies demonstrate that PRIMA-1 restores the
p53-Hsp90α  interaction, enhances the translocation of the p53-
Hsp90α  complex and reactivates p53 transcriptional activity.
Our preliminary evidence also suggests that PRIMA-1 could be
considered in combination therapy with DNA-targeted agents
for the treatment of breast cancer, especially for tumors with
aberrant p53 function.
Introduction
Many clinical studies have shown that mutations in p53 are a
strong predictor of relapse and are associated with resistance
to several therapeutic regimens [1,2]. Studies in our laborato-
ries and others, for example, showed that mutations in p53 in
human tumor cells were correlated with decreased sensitivity
to DNA-damaging agents [3-6]. An improved understanding of
the relationship between p53  and chemosensitivity might
therefore lay the groundwork for new cancer therapies. To
understand this relationship better, we recently used a
DAPI = 4',6-diamidino-2-phenylindole; Hsp90α  = heat shock protein 90, α  isoform; Hsp90β  = heat shock protein 90, β  isoform; MALDI-TOF = matrix-
assisted laser desorption ionization-time-of-flight; NE = nuclear extracts; NLS = nuclear localization signal; PBS = phosphate-buffered saline; PFTα  
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pharmacogenomic approach with complementary DNA micro-
arrays to characterize gene expression profiles of cells con-
taining wild-type p53 (p53+/+) and those containing an
isogenic p53 knockout counterpart (p53-/-) after treatment
with topotecan, a specific topoisomerase I inhibitor and a
DNA-targeted agent [7]. About 10% of the transcripts
detected were differentially expressed in the p53+/+ cells in
response to topotecan, whereas only 1% of the transcripts
changed in the p53-/- cells [7]. These data clearly showed the
broad effect of p53 on the transcriptional response to DNA
damage, which can lead to growth arrest or apoptosis.
Given that p53 is the most commonly mutated gene in human
cancers and that more than 50% of breast tumors are defec-
tive in p53 [8-10], extensive research efforts are centered on
restoring normal function to mutant p53 to promote tumor sup-
pression. This effort includes the use of modifying peptides
[11,12], antisense oligonucleotides [13] and small molecules
[14,15]. Unfortunately, the problem of in vivo delivery and lack
of selectivity to tumor cells has limited the practical application
of most of these efforts. Recently, PRIMA-1 has emerged from
an in vitro screen of small molecules that reactivate the tran-
scriptional activity of mutant p53 [16]. PRIMA-1 has the capa-
bility of restoring the transcriptional transactivation function to
mutant p53 in vitro and in vivo with subsequent tumor regres-
sion. PRIMA-1 also has the ability to trigger apoptosis in tumor
cells as a function of its mutant p53 reactivation response
[17]. We reported recently [18] that PRIMA-1 (in a effect
dependent on both dose and time) restored the transcriptional
activity of p53 target genes such as p21Waf1/cip1 in breast can-
cer cells possessing a p53  mutation. However, the exact
molecular mechanisms for mutant p53 reactivation by PRIMA-
1 are not yet determined. A direct interaction between PRIMA-
1 and p53 has not yet been demonstrated. It is possible that
PRIMA-1 affects cellular chaperones, resulting in the refolding
of mutant p53. Alternatively, PRIMA-1 may block complex for-
mation between mutant p53 and p73, leading to the release of
active p73, which triggers proapoptotic target genes [15]. To
identify the possible molecular candidates of mutant p53 reac-
tivation by PRIMA-1 in breast tumor cells, in this study we used
tools available for a functional proteomics approach.
Our study indicates that the restoration of the transcriptional
transactivation of p53  target genes such as p21Waf1/cip1 is
dependent on p53 and that the α  isoform of heat shock pro-
tein 90 (Hsp90α ) is associated with mutant p53 reactivation
by PRIMA-1. As a result of refolding of mutant p53 by Hsp90,
we show that both p53 and Hsp90α  are translocated to the
nucleus of the tumor cells for the activation of p53 target
genes. The use of PRIMA-1 to reactivate mutant p53 may
therefore be considered further as an approach for adjuvant
chemotherapy in the treatment of breast tumors, especially in
cancers with aberrant p53 function.
Materials and methods
Drugs and materials
PRIMA-1 (NSC-281668) was obtained from the Drug Synthe-
sis and Chemistry Branch, National Cancer Institute
(Bethesda, MD); pifithrin-α  (PFTα ) and doxorubicin (adriamy-
cin hydrochloride) were purchased from Biomol Research Inc.
(Plymouth Meeting, PA). Primary antibodies against p53 and
p21 were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA); Hsp 90 primary antibodies were from Stressgen
(Victoria, BC, Canada). The goat anti-mouse, anti-rat and anti-
rabbit secondary antibodies labeled with IRDye™ 38 were pur-
chased from LI-COR, Inc. Biosciences (Lincoln, NE) or with
Alex680 from Molecular Probes, Inc. (Eugene, OR). All other
chemicals were of reagent grade.
Cell and culture conditions
The human MCF-7 breast carcinoma cells (p53+/+), MDA-MB-
231 and GI-101A (p53 mutant) were routinely maintained in
monolayer cultures in RPMI-1640 medium (Invitrogen, Inc.,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(Hyclone, Logan, UT) as reported previously [3]. As we
reported previously [18], p53 protein in GI-101A cells con-
tains mutations at Y236C, A278P and R72P, whereas p53
protein in MDA-231 cells contains mutations at A278P,
R280K and M385T. Exponentially growing cultures at 80%
confluence were used in all experiments. For cytotoxicity
assays, cells from exponentially growing cultures were plated
in 24-well tissue culture plates in RPMI-1640 medium plus
10% fetal calf serum at about 104 cells per well, and the IC50
doses of PRIMA-1 in MDA-231 and GI-101A cells were deter-
mined as reported previously [18]. For drug combination stud-
ies, we used 100 µM PRIMA-1 and 0.2 µM adriamycin. Both
cell lines were treated with the following drug sequence: A3,
cells were treated with adriamycin for 3 hours; A24, cells were
treated with adriamycin for 24 hours; P24, cells were treated
with PRIMA-1 for 24 hours; AP24, cells were treated with both
adriamycin and PRIMA-1; and A3P24, cells were treated with
adriamycin for 3 hours followed by the removal of adriamycin-
containing medium, washing with fresh medium and then incu-
bation with PRIMA-1 for 24 hours. Each treatment was per-
formed in quadruplicate wells in two independent
experiments. The wells were washed twice with prewarmed
medium, followed by the addition of 2 ml of drug-free medium.
The plates were then incubated for a further 3 days. The sur-
viving fraction of cells was determined with the crystal violet
assay, as reported previously [19]. The precision of this
method with quadruplicate determinations is 10% (SD). The
data were analyzed with Student's two-tailed t-test; P < 0.01
was considered statistically significant.
Immunoblotting and immunoprecipitation
Cells were incubated with 0 or 100 µM PRIMA-1 for 0, 2, 4 or
8 hours, then washed twice with PBS (pH 7.4) and harvested.
Harvested cells were either used to prepare whole cell lysates
or for subcellular fractionation studies. Cell lysates wereAvailable online http://breast-cancer-research.com/content/7/5/R765
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prepared as described previously [7]. For immunoblotting, 20
µg protein samples were separated by SDS-PAGE (4 to 20%
polyacrylamide gradient gel) and transferred on nitrocellulose
(Millipore, Bedford, MA). The membrane was developed in
accordance with a protocol provided by LI-COR, Inc. Bio-
sciences using anti-β -actin, anti-p53 and anti-p21 primary anti-
bodies (Santa Cruz Biotechnology) or anti-Hsp90α  and anti-
Hsp90β  primary antibodies (Stressgen). The goat anti-mouse,
anti-rat and anti-rabbit secondary antibodies labeled with
IRDye™ 38 (ex/em: 774/800 nm; LI-COR) or with Alexafluor®
680 (ex/em: 680/707 nm; Molecular Probes) were used. The
reactive bands were revealed and detected with the Odys-
sey™ Infrared Imaging System (LI-COR, Inc.).
For immunoprecipitation studies, 107 MDA-MB-231 or GI-
101A cell cultures were grown in T-150 tissue culture flasks.
Cultures were treated with 100 µM PRIMA-1 for 4 hours.
Cleared cell lysates (total 1 mg of protein) were immunopre-
cipitated either with 5 µg of DO-1 anti-p53 monoclonal anti-
body or 5 µg of anti-Hsp90α  monoclonal antibody in a co-
immunoprecipitation assay in accordance with the protocol
provided by eBiosciences, Inc. (San Diego, CA) using Protein
A or G-plus agarose beads (Santa Cruz Biotechnology). After
SDS-PAGE (4 to 20% polyacrylamide), gels were either
stained with Coomassie blue (Bio-Rad, Inc., Hercules, CA) or
subjected to immunoblotting.
In-gel enzymatic digestion and mass spectrometry
The protein bands were excised from the one-dimensional
Coomassie blue-stained polyacrylamide gel shown in Fig. 1.
After reduction and alkylation the protein bands were dehy-
drated in acetonitrile and dried. The bands were digested in
the gel with an excess of sequencing-grade trypsin (Promega,
Madison, WI). The digestion was performed overnight at
37°C. The resulting tryptic peptides were extracted from the
gels, then desalted and concentrated with C18 ziptip (Milli-
pore) before spotting for matrix-assisted laser desorption ioni-
zation-time-of-flight (MALDI-TOF) analysis.
An OmniFlex MALDI-TOF mass spectrometer (Bruker Dalton-
ics, Billerica, MA) was used for peptide mass fingerprinting.
Desalted peptide solution (1 µl) was mixed with 1 µl of matrix
solution (α -cyano-4-hydroxycinnamic acid in 0.1% trifluoro-
acetic acid and 50% acetonitrile) and was then spotted
directly on the MALDI target. All data used for protein identifi-
cation and calibration were acquired in reflectron mode and
averaged for 100 shots. These studies employed external
mass calibration and used angiotensin I, corticotropin (ACTH)
clip (1 to 17) and ACTH clip (18 to 39) peptides as calibrants.
After spectral acquisition, the peak m/z values were extracted
and used to search the Swiss Protein Database with the Pro-
Found program [20] search engine. The database search was
performed with an implementation of the following search
parameters: taxonomy (Homo sapiens), enzyme (trypsin),
missing cleavage, mass tolerance (0.24 Da), modification (car-
bamidomethyl for cysteine and oxidation for methionine) and
database (NCBRnr).
Subcellular fractionation and immunocytochemistry
To determine the nuclear translocation of p53 and Hsp90α ,
cells treated with PRIMA-1 were subjected to nuclear isolation
with the FOCUS cytoplasmic and nuclear protein extraction kit
(Geno Technology, Inc., St. Louis, MO) in accordance with the
manufacturer's instructions. A fraction of the isolated nuclear
pellet was fixed in 4% paraformaldehyde in 1 × PBS to deter-
mine the intactness of nuclei by staining with 4',6-diamidino-2-
phenylindole (DAPI). Fixed nuclei were mounted on Super-
Frost-plus slides (Fisher Scientific, Pittsburgh, PA) with Pro-
long Gold antifade reagent with DAPI (Molecular Probes,
Invitrogen Detection Technologies, Carlsbad, CA). Our
nuclear preparation contained 99% intact nuclei. To determine
the expression of p53, and Hsp90s in intact nuclear fractions,
the nuclear pellet was lysed into 1 × SDS sample buffer and
subjected to denaturing gel electrophoresis followed by immu-
noblotting as described above.
Figure 1
Coomassie blue-stained gel of proteins co-immunoprecipitated with  DO-1 primary antibody from MDA-MB-231 cells Coomassie blue-stained gel of proteins co-immunoprecipitated with 
DO-1 primary antibody from MDA-MB-231 cells. Cleared cell lysates 
were immunoprecipitated with DO-1 primary antibody directed against 
p53, washed, and resolved by SDS-PAGE (4 to 20% polyacrylamide). 
Two independent co-immunoprecipitated samples from untreated con-
trol (-) and cells treated for 4 hours with 100 µM PRIMA-1 (+) were 
loaded. The gels were stained with Coomassie blue. Molecular masses 
of protein size markers are indicated (MW). The arrowhead indicates 
the band of stained proteins excised for enzymatic digestion by trypsin 
and subsequent mass fingerprinting with matrix-assisted laser desorp-
tion ionization-time-of-flight mass spectrometry.Breast Cancer Research    Vol 7 No 5    Rehman et al.
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To confirm translocation of proteins into the nucleus, nuclear
fractions were subjected to immunostaining for p53 and
Hsp90α . Immunocytochemistry was performed in accordance
with a previously described protocol, with modifications [21].
In brief, fixed nuclear fractions were suspended in antibody
buffer (0.1 M PBS, pH 7.4, containing 0.1% Triton X-100) and
incubated overnight at 4°C with mouse monoclonal anti-p53
(DO-1) and rat monoclonal anti-Hsp90α  antibody at 50:1 dilu-
tion. In addition, all appropriate negative controls without the
primary antibodies were run in parallel. Unbound antibodies
were removed by centrifuging nuclear preparations at 800 g
for 3 min at room temperature (22–24°C) followed by three
subsequent 5 min washes with shaking (300 r.p.m.) in anti-
body incubating buffer at room temperature. Next, the bound
primary antibody was detected by using species-specific sec-
ondary antibody conjugated with different fluorescent dyes at
100:1 dilution in antibody incubation buffer at room tempera-
ture for 1 hour. The mouse IgG secondary antibody conju-
gated with Oregon green was used to detect mouse
monoclonal antibody against p53 (DO-1) and the rat IgG sec-
ondary antibody conjugated with Texas red was used to detect
rat monoclonal antibody against Hsp90α  (Molecular Probes,
Invitrogen Detection Technologies). The unbound secondary
antibody was removed by using three washes as described
earlier for primary antibody. After three washes, nuclear frac-
tions were diluted in antibody incubating buffer without Triton
X-100 and spread onto a SuperFrost-plus slides. The air-dried
slides were then coverslipped with medium containing the
nuclear stain DAPI, as before. The immunofluorescence for
DAPI, Texas Red and Oregon green was detected with an Axi-
oplan 2 epifluorescent microscope (Zeiss, Thornwood, NY)
equipped with appropriate filters. Individual nuclei were visual-
ized at × 20 magnification.
Results and discussion
Inhibition of transcriptional reactivation function of p53 
with PFTα
We previously reported that PRIMA-1 restored the transcrip-
tional activity of p53 target genes, such as p21Waf1/cip1, in
breast cancer cells [18]. The IC50 values for PRIMA-1 in MDA-
231, GI-101A and MCF-7 cells were determined as 141, 51
and 122 µM, respectively. We selected p21Waf1/cip1  as a
marker for measuring the extent of the transcriptional reactiva-
tion of p53 by PRIMA-1 at both mRNA and protein levels,
because the promoter of the p21 gene exhibits high occu-
pancy to wild-type p53 protein on its p53 binding sites, in vivo;
it is therefore considered a benchmark for p53-dependent
genes [22]. However, p21Waf1/cip1 can also be transcriptionally
regulated by p53-independent mechanisms [23,24]. To deter-
mine whether the expression of p21Waf1/cip1 is dependent on
the restored transcriptional function of p53, cells were treated
with PRIMA-1 in the presence and in the absence of PFTα .
PFTα  is a small molecule that was isolated for its ability to
block p53-dependent transcriptional activation [25]. As
shown in Fig. 2, treatment of GI-101A cells (mut p53) with
100 µM PRIMA-1 induced the expression of p21Waf1/cip1 at 4
hours. However, treatment of these cells with PRIMA-1 in the
presence of 20 µM PFTα  resulted in an inhibition of p21Waf1/
cip1 expression. No change in the level of p53 protein was
observed under these conditions. In contrast, no change in the
expression of p21Waf1/cip1 protein was observed when MCF-7
cells (wild-type p53) were treated with PRIMA-1 in the pres-
ence of PFTα , confirming the specificity of action of PFTα  as
an inhibitor of p53-dependent transcriptional function. The
lack of inhibition of p21 expression in MCF-7 cells after treat-
ment with PFTα  suggests that there is p53-independent
expression of p21 in these cells or that MCF-7 cells is not sen-
sitive to the dosage of PFTα  used in our studies. Furthermore,
the data also show that mutant p53 reactivation by PRIMA-1
results in the transcriptional activation of p53 target genes
such as p21Waf1/cip1. However, the exact molecular mecha-
nisms by which this activation occurred are not yet deter-
mined. Identification of the molecular targets that are involved
in mutation reactivation of p53 by PRIMA-1 is essential for
understanding the molecular mechanisms for p53 mutation
reactivation and for devising therapeutic strategies aimed at
enhancing the use of PRIMA-1 in cancer therapy. It is conceiv-
ably possible, for example, that PRIMA-1 affects cellular chap-
erones resulting in the refolding of mutant p53. In an attempt
to identify possible molecular targets involved in mutation
reactivation of p53 by PRIMA-1, we used a functional pro-
teomics approach in which cell lysates were co-immunopre-
cipitated with DO-1 primary antibody directed against p53
Figure 2
Inhibition of PRIMA-1 mediated transcriptional reactivation function of  p53 with pifithrin-α  (PFTα ) Inhibition of PRIMA-1 mediated transcriptional reactivation function of 
p53 with pifithrin-α  (PFTα ). MCF-7 (p53+/+) and GI-101A (mut p53) 
cells were treated with 100 µM PRIMA-1 for 2, 4 and 8 hours (lanes 1, 
2 and 3, respectively). Cells were treated with 20 µM PFTα  for 6 hours 
(lane 4) or with 20 µM PFTα  for 2 hours followed by PRIMA-1 for 4 
hours (lane 5). 20 µg of protein samples of cell lysates were separated 
by SDS-PAGE (4 to 20% polyacrylamide) and subjected to Western 
blot analysis with p53 and p21 primary antibodies. The reactive bands 
were revealed and detected with the Odyssey™ Infrared Imaging Sys-
tem. β -Actin was used as a loading control for protein samples.Available online http://breast-cancer-research.com/content/7/5/R765
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after treatment with PRIMA-1 followed by protein partner iden-
tification with MALDI-TOF mass spectrometry.
Identification of Hsp90 as a candidate target for p53 
mutation reactivation
Figure 1 shows a Coomassie blue-stained gel of proteins co-
immunoprecipitated with DO-1 antibody from MDA-MB-231
cells (mut p53) after treatment with 100 µM PRIMA-1 for 4
hours. We chose to resolve proteins by one-dimensional elec-
trophoresis because we were able to observe clearly and
reproducibly the separation of protein mixtures, especially that
of proteins smaller than 100 kDa. Single bands of polyacryla-
mide gel slices from SDS-PAGE that are differentially
expressed after treatment with PRIMA-1 were excised and
subjected to in-gel digestion by trypsin. After digestion, a small
portion of the supernatant was removed and analyzed by high-
accuracy peptide mass mapping with MALDI. The peptide
masses obtained by MALDI analysis were used to search pro-
tein databases. We routinely observe peaks that correspond
to keratin, presumably resulting from contamination during the
handling of gel slices. Such peaks were excluded from our
analysis and were occasionally used for internal calibration.
Figure 1 focuses on a single band (90 kDa) that is marked by
an arrow because it is one of the bands that is distinctly
expressed in MDA-MB-231 cells after treatment with PRIMA-
1 and co-immunoprecipitated with DO-1 monoclonal anti-
body. The tryptic digests of the excised bands were subjected
to mass fingerprinting with the MALDI-TOF mass spectrum as
reported previously [26]. Figure 3 illustrates the MALDI mass
spectrum acquired from the peptide mixture resulting from in-
gel digestion of the 90 kDa bands shown in Fig. 1. On aver-
age, six peptide masses were identified in this spectrum that
agreed with the expected peptide masses within a mass toler-
ance of ± 0.24 Da. The peak m/z values were used to search
the SwissProt Database with the ProFound program. This
search resulted in the identification of Hsp90 (Klenow frag-
Figure 3
Peptide mass fingerprinting of in-gel tryptic digest of the 90 kDa band generated with a matrix-assisted laser desorption ionization-time-of-flight mass  spectrometer Peptide mass fingerprinting of in-gel tryptic digest of the 90 kDa band generated with a matrix-assisted laser desorption ionization-time-of-flight mass 
spectrometer. Protein bands indicated by the arrowhead in Fig. 1 were subjected to in-gel digestion and analyzed by mass spectrometry. The tryptic 
peptides from this band showed the presence of six peptides corresponding to heat shock protein 90 (Hsp90) as one of the proteins that were 
found in the altered protein-protein interaction pattern of p53 with and without PRIMA-1 treatment.
Figure 4
Protein-protein interaction analysis of p53 and the α  isoform of heat  shock protein 90 (Hsp90α ) Protein-protein interaction analysis of p53 and the α  isoform of heat 
shock protein 90 (Hsp90α ). (a) MDA-231 cell lysates from untreated 
cells (lanes 1 and 3) and cells treated for 4 hours with 100 µM PRIMA-
1 (lanes 2 and 4) were immunoprecipitated (IP) with anti-Hsp90α  mon-
oclonal antibody and subjected to Western blotting (WB) with anti-p53 
(DO-1) monoclonal antibody (lanes 1 and 2) in addition to reciprocal 
immunoprecipitation with DO-1 and Western blotting with anti-Hsp90α  
(lanes 3 and 4). (b) GI-101A cell lysates from untreated cells (lanes 1 
and 3) and cells treated for 4 hours with 100 µM PRIMA-1 (lanes 2 and 
4) were immunoprecipitated with anti-Hsp90α  monoclonal antibody 
and subjected to Western blotting with anti-p53 (DO-1) monoclonal 
antibody (lanes 1 and 2) in addition to reciprocal immunoprecipitation 
with DO-1 and Western blotting with anti-Hsp90α  (lanes 3 and 4).Breast Cancer Research    Vol 7 No 5    Rehman et al.
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ment) with a probability score of 1.0 and Z score of 1.8, a
strong identification of this protein. The sequence coverage of
the matched protein candidate (Klenow fragment) was 27%.
These results were repeated with multiple co-immunoprecipi-
tation experiments, which all resulted in the identification of
Hsp90α  as a candidate protein that is differentially expressed
after treatment of cells with PRIMA-1.
Because the data collected by peptide mass fingerprinting are
sometimes insufficient for the reliable identification of a pro-
tein, we further validated and confirmed the identity of Hsp90
protein by immunoblotting analyses. Cells were treated with
100 µM PRIMA-1 for 2, 4 or 8 hours, and protein samples from
the whole cell extracts (WCE) and nuclear extracts (NE) were
Western blotted with antibodies directed against both the α
and β  forms of Hsp90 protein. In mammalian cells there are at
least two Hsp90 isoforms, Hsp90α  and Hsp90β , which are
encoded by separate genes. The amino acid sequences of
human and yeast Hsp90α  are 85% and 90% homologous to
Hsp90β , respectively [27]. All known members of the Hsp90
protein family are highly conserved, especially in the amino-ter-
minal and carboxy-terminal regions that contain independent
chaperone sites with different substrate specificity [28,29]. To
confirm the interaction of p53 with Hsp90α , we performed a
co-immunoprecipitation assay with monoclonal Hsp90α  anti-
body on control cells and PRIMA-1-treated cells and sub-
jected the immunoprecipitated proteins to immunoblotting
with monoclonal antibody against p53 protein (DO-1). As
shown in Fig. 4, both MDA-231 and GI-101A cells exhibited
interaction of p53 with Hsp90α  protein. The data indicate that
p53 interacts with Hsp90α  in both breast cancer cells. How-
ever, the p53 and Hsp90α  protein-protein interaction is differ-
ent in both cell lines. For example, GI-101A cells show no
noticeable changes in protein-protein interaction after
treatment with PRIMA-1 (Fig. 4b), whereas more Hsp90α  is
bound to p53 in MDA-231 cells after treatment with PRIMA-1
(Fig. 4a). This may reflect the phenotype of cells as well as dif-
ferences in p53 mutations and polymorphism [16].
Nuclear translocation of Hsp90α  after treatment with 
PRIMA-1
The Western blots in Fig. 5a show that both isoforms of
Hsp90 are expressed in both cell lines, although in different
amounts. The α -isoform is expressed in greater amounts than
the β -isoform in samples obtained from both WCE and NE. In
addition, Hsp90α  was detected in the NE of protein samples
obtained from both cell lines. The level of Hsp90α  in the NE
was increased after treatment of cells with PRIMA-1 for 8
hours. In contrast, the Hsp90β  isoform was not detected in the
NE of protein samples obtained from either cell line, suggest-
ing that only the α  isoform of Hsp90 is translocated to the
nucleus after treatment with 100 µM PRIMA-1. The exact
mechanism(s) for this differential translocation are not clear
yet. However, the intracellular localization of Hsp90 has been
investigated under normal and heat-stressed conditions. After
heat stress, an increased amount of Hsp90α  was detected in
the nucleus of cells compared to unstressed cells[30,31]. For
nuclear localization to occur, the nuclear localization signal
(NLS) is usually required. For Hsp90α , as well as for many
other proteins, the nuclear import is recognized by an NLS
receptor (a heterodimeric complex) that is composed of impor-
tin α  and β  subunits [32-34]. It has been shown that, under in
vitro conditions, Hsp90α  interacts with importin α  [31].
It is also possible that the nuclear transport of Hsp90α  after
treatment with PRIMA-1 constitutes part of a selective delivery
of restored conformation of p53 to the nucleus. The nuclear
transport of the wild-type p53 is also known to be dependent
on NLS systems [34]. We therefore investigated whether the
observed nuclear accumulation of Hsp90α  after treatment
with PRIMA-1 was correlated with any changes in p53 protein
expression and/or localization. Figure 5b shows the nuclear
accumulation of p53 after treatment of cells with 100 µM
PRIMA-1 for 2, 4 or 8 hours. The ratio of the integrated absorb-
ance of p53 bands to that of the actin band was used as an
index of protein expression in both WCE and NE. It is clearly
shown in Fig. 5b that the levels of p53 protein in the NE are
much higher after the treatment of both cell lines with PRIMA-
1, especially at 8 hours, indicating that the observed increase
of Hsp90α  protein levels in the NE (Fig. 5a) is correlated with
that of p53 protein nuclear accumulation. We observed no
change in the level of p53 protein expression or localization
when MCF-7 cells were treated with PRIMA-1 (data not
shown). These data therefore suggest that the Hsp90 protein
is a binding partner to p53 after its conformational restoration
by PRIMA-1 and that the α -isoform is involved in the nuclear
accumulation of the active form of p53 protein. The enhanced
nuclear translocation of Hsp90α  was also investigated with
immunocytochemistry. Figure 6 shows that Hsp90α  is selec-
tively localized in the nucleus of MDA-231 breast cancer cells
treated with PRIMA-1 for 8 hours.
Many studies showed that the Hsp90 protein has a major role
in the stability of p53 protein and in its translocation to the
nucleus. King and colleagues [35] reported that the wild-type
p53 protein forms a complex with Hsp90 in the presence of
Hop and that Hsp90 may assist p53 import into the nucleus.
However, the type of Hsp90 isoform that is actually involved in
the nuclear translocation of p53 was not mentioned in that
study. Chen and Wang [36] recently reported that the stabili-
zation of p53 conformation after heat shock is associated with
its binding to Hsp90 protein and that the phosphorylation of
p53 is dependent on the Ataxia-telangiectasia-mutated protein
kinase (ATM)-mediated activation of human checkpoint 2
(ChK2) kinase. Although these studies investigated the role of
Hsp90 in regulating p53 stability under stressful conditions
(heat shock), the present studies confirmed the association
between Hsp90 and p53 under non-stressful conditions,
because there was no increase in Hsp90 expression in WCE
in PRIMA-1-treated cells (Fig. 5b), although a small decreaseAvailable online http://breast-cancer-research.com/content/7/5/R765
R771
in WCE of PRIMA-1-treated samples at 8 hours was
concomitant with an increase in nuclear translocation of
Hsp90α  in both cell lines.
Recently, Walerych and colleagues [37] reported that
Hsp90α  interacts with wild-type p53 protein and that this
interaction facilitates the binding of Hsp90α  to the p21 pro-
moter in ATP-dependent manner. Murphy and colleagues [38]
showed that PFTα  inhibits the p53 signaling after interaction
with Hsp90α . Thus, both reports [37,38] suggest that the
interaction of p53 and Hsp90α  enhances the transcriptional
transactivation of genes containing p53-binding sites in their
promoter region. Our findings can be interpreted as the resto-
ration of the p53-Hsp90α  interaction by PRIMA-1, enhancing
the nuclear translocation of p53-Hsp90α  and reactivating the
transcriptional activity of p53.
Sensitization of breast cancer cells to DNA targeted 
agents with PRIMA-1
We next examined whether reactivation of the p53 mutation by
PRIMA-1 would enhance the cytotoxicity of DNA-damaging
agents such as adriamycin in vitro. Because many studies
have shown that p53 mutations are associated with a
decreased sensitivity of tumor cells to many chemotherapeutic
agents [3-6,39], it seems reasonable that PRIMA-1, which
restores p53 transcriptional activity and enhances its nuclear
translocation, would increase the sensitivity of these cells to
DNA-targeted agents. Figure 7 shows that simultaneous treat-
ment of human breast cancer MDA-231 and GI-101A cells in
vitro with 100 µM PRIMA-1 and 0.2 µM adriamycin for 24
hours, or sequential treatment with adriamycin for 3 hours fol-
lowed by PRIMA-1 for 24 hours, significantly enhances the
sensitivity of tumor cells to the drug combination compared
with the use of each drug alone. On close examination of the
percentage of cell survival after drug treatment of MDA-231
Figure 5
Western blots of heat shock protein 90 (Hsp90) proteins from control and PRIMA-1-treated cells Western blots of heat shock protein 90 (Hsp90) proteins from control and PRIMA-1-treated cells. Cells were treated with 100 µM PRIMA-1 for 2, 4 
or 8 hours. 20 µg of protein samples of cell lysates from the whole cell extracts (WCE) and nuclear extracts (NE) of the control (C) and treated sam-
ples were separated by SDS-PAGE (4 to 20% polyacrylamide) and Western blotted with antibodies directed against both the α  and β  isoforms of 
Hsp90 (a) and against p53 (b). β -Actin was used as a loading control. The reactive bands were detected with the Odyssey™ Infrared Imaging 
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cells, it is clearly shown that adriamycin treatment for 3 hours
(A3) had 95% cell survival, compared with only 30% in the
presence of PRIMA-1 (A3P24). Treatment of these cells for 24
hours with PRIMA-1 alone produced 75% cell survival. These
data suggest that PRIMA-1 enhances adriamycin efficacy and
that the drug combination, in this case, is synergistic or supra-
additive. Preliminary evidence from our laboratory indicates
that the drug combination is also synergistic on a panel of
breast cancer cell lines (Tao Wang and S.S.D., unpublished
work).
Conclusion
This study illustrates the use of a functional proteomics
approach to identify target molecules that are associated with
the reactivation of a p53 mutation by PRIMA-1. Our approach
has identified Hsp90α  as a partner protein that is associated,
in part, with the restoration of p53 transcriptional transactiva-
tion function by PRIMA-1. We also showed that the α  isoform
of Hsp90 protein is associated with the nuclear translocation
of p53 protein after treatment of breast tumor cells with
PRIMA-1. Our results that PFTα  inhibits the induction of p21
expression after treatment with PRIMA-1, and the recent work
of Murphy and colleagues [38] indicating that PFTα  inhibits
the signaling of p53-mediated gene transcription, strongly
suggest that PRIMA-1 facilitates the interaction of Hsp90α
and the restoration of mutant p53 to wild type followed by the
Figure 6
The nuclear localization of the α  isoform of heat shock protein 90 (Hsp90α ) is enhanced by treatment of cells with PRIMA-1 The nuclear localization of the α  isoform of heat shock protein 90 (Hsp90α ) is enhanced by treatment of cells with PRIMA-1. MDA-231 cells treated 
with PRIMA-1 were subjected to nuclear isolation. A fraction of the isolated nuclear pellet was fixed in 4% paraformaldehyde, permeabilized in 0.1% 
Triton X-100 and incubated overnight with anti-p53 and anti-Hsp90α  monoclonal antibodies. Nuclear fractions were then immunostained with a sec-
ondary antibody conjugated with Oregon green to detect p53 (green) and a secondary antibody conjugated with Texas red to detect Hsp90α  (red) 
before detection by fluorescence microscopy. Nuclei were stained with 4',6-diamidino-2-phenylindole (blue). Normal mouse immunoglobulin G was 
used as a negative control (data not shown). Arrows mark nuclear staining of Hsp90α . Scale bar, 5 µm.
Figure 7
Combination and sequential exposure of cells to PRIMA-1 and  adriamycin Combination and sequential exposure of cells to PRIMA-1 and adriamy-
cin. Exponentially growing MDA-MB-231 or GI-101A cells were 
seeded in 10% serum-supplemented RPMI-1640 medium at 104 cells 
per well. After 24 hours, cells were treated with 100 µM PRIMA-1 for 
24 hours (P24), 0.2 µM adriamycin for 3 hours (A3) or 24 hours (A24), 
and a combination of PRIMA-1 plus adriamycin for 24 hours (AP24) or 
adriamycin for 3 hours followed by PRIMA-1 for 24 hours (A3P24). 
After drug treatment, the cells were reincubated in drug-free medium 
for a further 3 days and cell survival was determined with the crystal vio-
let assay. Results are means ± SD for quadruplicate determinations 
(SD<10%) representative of two to four independent experiments; 
P<0.01.Available online http://breast-cancer-research.com/content/7/5/R765
R773
translocation of both proteins into the nucleus. This may result
in the transactivation of genes containing p53-binding sites as
reported by Walerych and colleagues [37].
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